Ürotelyal Displazi

Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of tumors of the urinary system and male genital organs. 4th edition. Lyon: International Agency for Research on Cancer; 2016.

Epstein Jonathan I, Reuter Victor E, Amin Mahul B. 2016. Mesane Biyopsilerinin Yorumu. Dilek Ertoy Baydar (s.22-34) İstanbul: Nobel Tıp Kitapevi

Mills Stacey E. 2016. Sternberg’s Diagnostic Surgical Pathology Türkçe. 6.Baskı. Gülen Bülbül Doğusoy. Volume 2 (s.2083-2085) Ankara: O Tıp Yayın Evi.

Peter A Humphrey , Holger Moch , Antonio L Cubilla , Thomas M Ulbright, Victor E Reuter. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. European Urology 2016, Jul;70(1):106-119.

Kurt B. Hodges MD, Antonio Lopez-Beltran, Darrell D. Davidson, Rodolfo Montironi, Liang Cheng. Urethelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Human Pathology, 2010, 41, 155-162.

Jesse K McKenney. Precursor lesions ot the urinary bladder. Histopathology, 2019 Jan;74(1):68-76.

Antonio Lopez-Beltran, Rita C. Marques, Rodolfo Montironi, Carlos Reymundo, Jorge Fanseca, Liang Cheng. Dysplasia and Carcinoma in situ of the Urinary Bladder. Analytical and Quantitative Cytopathology and Histopathology, 2015, Feb;37(1):29-38.

Yörükoğlu K, Tuna B.2016. Üropatoloji (s.179-180) İzmir: Kongre Kitabevi.

Margaret E. Lawless, Maria S. Tretiakova, Lawrence D. True, Funda Vakar-Lopez. Flat Urethelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling. Applied Immunohistochemistry and Molecular Morphology. 2018 Mar;26(3):180-185.

Mojgan Asgari, Mahtab Nabi Maybodi, Maryam Abolhasani. Differeantial diagnosis of urethelial carcinoma in situ from non-neoplastic urethelia: Analysis of CK20, CD44, P53 and Ki-67. Medical Journal of the Islamic Republic of Iran. 2016; 30: 400.

Damian Jaworski, Lukasz Szylberg , Arkadiusz Gzil , Peter Stawinski , Anna Kasperska , Andrzej Marszałek . Diagnostic difficulties in cases of papillary urothelial neoplasm of low malignant potential, urothelial proliferation of uncertain malignant potential, urothelial dysplasia and urothelial papilloma: A review of current literature. Ann Diagn Pathology, 2019 Jun;40:182-188.

Mahul B Amin, Kiril Trpkov, Antonio Lopez-Beltran, David Grignon, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol . 2014 Aug;38(8):e20-34.

Paulette Mhawech-Fauceglia , Richard T Cheney, Juerg Schwaller. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer, 2006 Mar 15;106(6):1205-16.

Benson RC Jr, Swanson SK, Farrow GM. Relationship of leukoplakia to urothelial malignancy. J Urol 1984; 131(3):507-511.

Stilmant M, Murphy JL, Merriam JC. Cytology of nephrogenic adenoma of the urinary bladder. A report of four cases. Acta Cytol 1986; 30(1):35-40.

Rutgers JL, Young RH. Nephrogenic adenoma of the urinary bladder: a comparison of its cytologic and histopathologic featuresin ten cases. Diagn Cytopathol 1988;4 (3):210-216

Tong GX, Melamed J, Mansukhani M, et al PAX-2: a reliable marker for nephrogenic adenoma. Mod Pathol 2006;19(3):356-363.

Herlitz LC, Tong GX, Hamele-Bena D, Greenebaum E. Nephrogenic adenoma identified on urine cytology using PAX-2 immunostaining. Diagn Cytopathol 2008;36(1):47-49.